[Pharmacoeconomic efficiency of sparfloxacin use in empiric therapy of community-acquired pneumonia].
Lazareva
N B
NB
D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D024841:Fluoroquinolones / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000453:epidemiology
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C061363:sparfloxacin